Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation

PURPOSE: Acquired resistance is a bottleneck that restricts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for lung cancer. Ginsenoside Rg3 is an antiangiogenic agent which can down-regulate the expressions of vascular endothelial growth factor (VEGF) and EGFR....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Li, Yan, Wang, Yanmei, Niu, Kai, Chen, Xiewan, Xia, Liqin, Lu, Dingxi, Kong, Rui, Chen, Zhengtang, Duan, Yuzhong, Sun, Jianguo
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342572/
https://ncbi.nlm.nih.gov/pubmed/27655708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12059
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados